Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting results tomorrow morning. Here’s what to look for.
NeoGenomics met analysts’ revenue expectations last quarter, reporting revenues of $167.8 million, up 10.4% year on year. It was a strong quarter for the company, with a solid beat of analysts’ EPS estimates.
Is NeoGenomics a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting NeoGenomics’s revenue to grow 11.7% year on year to $173.8 million, in line with the 12.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.03 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. NeoGenomics has missed Wall Street’s revenue estimates three times over the last two years.
Looking at NeoGenomics’s peers in the healthcare providers & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Quest delivered year-on-year revenue growth of 14.6%, beating analysts’ expectations by 1.8%, and Labcorp reported revenues up 9.8%, topping estimates by 0.6%. Quest traded up 5% following the results, while Labcorp was down 1.3%.
Read our full analysis of Quest’s results here and Labcorp’s results here.
Inflation has progressed towards the Fed’s 2% goal as of late, leading to strong stock market performance. Recent rate cuts and the 2024 Presidential election’s conclusion added further sparks to the market, and while some of the healthcare providers & services stocks have shown solid performance, the group has generally underperformed, with share prices down 2.3% on average over the last month. NeoGenomics is up 2.8% during the same time and is heading into earnings with an average analyst price target of $20.45 (compared to the current share price of $14.57).
Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
